Book a Meeting

BetterBet™ Anti-CD19 Recycling Antibody (CAT#: AES-0622-ZP48) Datasheet

Target
CD19
Description
Therapeutic antibodies help improve treatment outcomes for certain disease conditions. However, even with infinite binding affinity for the antigen, conventional antibodies can only bind to the antigen once and lead to an increase in the total plasma antigen concentration in the body. This antibody-mediated antigen accumulation usually occurs because the clearance of antibody-antigen complexes from the circulation is much slower than that of free antigen. This limitation can be overcome by recycling/sweeping antibodies, which actively eliminate circulating soluble antigens. They are pH-responsive antibodies capable of binding the target antigen in a pH-dependent manner.

Creative Biolabs provides recycling antibody engineering services. This allows antibodies to not only bind to target antigens in plasma, but also eliminate or remove them. These engineered antibodies are expected to enhance cellular uptake of antibody-antigen complexes.
Applications
Enhanced mouse antigen eliminating
Technology
Antibody variable/constant engineering
Official Name
CD19
Full Name
CD19 molecule
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

A recycling antibody combines two antibody engineering techniques: one is variable region engineering, which enables the antibody to bind to the antigen in the plasma and dissociate from the antigen in the endosome (after which the antigen undergoes lysosomal degradation), the other is constant region engineering to increase cellular uptake of antibody-antigen complexes into endosomes.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK